One Hundred Vaccines Against COVID-19 Are In Early Stages of Development, But Only a Few Will Survive
source: pixabay.com

One Hundred Vaccines Against COVID-19 Are In Early Stages of Development, But Only a Few Will Survive

A total of one hundred vaccines are being developed by researchers, drug manufacturers, and governments worldwide in an effort to stem the tide of the COVID-19 virus. Reuters Newswire reports…

Continue Reading One Hundred Vaccines Against COVID-19 Are In Early Stages of Development, But Only a Few Will Survive
PTC Therapeutics to Acquire Censa Pharmaceuticals, Developer of an Experimental Phenylketonuria Drug
source: pixabay.com

PTC Therapeutics to Acquire Censa Pharmaceuticals, Developer of an Experimental Phenylketonuria Drug

According to a story from Xconomy, the drug company PTC Therapeutics has come to an agreement that will allow it to acquire Censa Pharmaceuticals and its lead product candidate. This…

Continue Reading PTC Therapeutics to Acquire Censa Pharmaceuticals, Developer of an Experimental Phenylketonuria Drug

Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier

It is acknowledged in the medical community that clumps of misfolded tau proteins and amyloid-β are markers of Alzheimer’s disease. The evidence presented in recent article in Nature, shows that…

Continue Reading Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier
Patients with Multiple Sclerosis Use Robotic Exoskeleton for Movement Improvement
https://pixabay.com/en/technology-robot-human-hand-2025795/

Patients with Multiple Sclerosis Use Robotic Exoskeleton for Movement Improvement

According to WMC5, a research study out of Cleveland, OH, has been testing the impact of robotic exoskeletons on movement for patients with multiple sclerosis. For Kathy Miska, this is…

Continue Reading Patients with Multiple Sclerosis Use Robotic Exoskeleton for Movement Improvement